Literature DB >> 7907918

Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.

J H Finke1, P Rayman, L Hart, J P Alexander, M G Edinger, R R Tubbs, E Klein, L Tuason, R M Bukowski.   

Abstract

The detection of T cells with specificity for human renal cell carcinoma (RCC) has been difficult to document. In an attempt to improve our identification of RCC-reactive T cells, tumor-infiltrating lymphocytes (TIL) were expanded in interleukin-2/interleukin-4 (IL-2/IL-4) and then separated into CD4+ and CD8+ subsets using antibody-coated biomagnetic beads. TIL grown in IL-2/IL-4 expanded to greater numbers than TIL grown in IL-2 alone. From 16 patients in whom subset separation was performed, three CD4+ and three CD8+ TIL consistently had specificity for RCC that was detected by cytotoxicity, proliferation, or interferon-gamma (IFN-gamma) production. Four of the six lines were derived from the IL-2/IL-4 cultures. Two CD8+ TIL lines displayed specific lytic activity, lysing the autologous tumor but not allogeneic RCC or nonrenal tumors. Moreover, the lytic activity of these lines was blocked by anti-CD3 antibody, suggesting that tumor recognition was through the TCR/CD3 complex. Two additional TIL lines showed preferential lysis of RCC because they were cytotoxic for autologous tumor and one or more allogeneic RCC but not other tumor types. Two nonlytic CD4+ lines as well as the two CD8+ lines that were specifically lytic also produced IFN-gamma in response to the autologous tumor but not allogeneic RCC. Although these TIL lines produce IFN-gamma when stimulated with tumor alone, the addition of 5 U/ml of IL-2 significantly enhanced IFN-gamma secretion. The four TIL lines that showed specificity for RCC in terms of IFN-gamma production also had enhanced proliferation to the autologous RCC plus IL-2 but not to multiple allogeneic RCC plus IL-2. These studies demonstrate that TIL from RCC patients contain both CD4+ and CD8+ T cells that have specificity for RCC. In addition to cytotoxicity, specificity to RCC can be defined by IFN-gamma production and proliferation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907918     DOI: 10.1097/00002371-199402000-00002

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN: 1067-5582


  6 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

2.  Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes.

Authors:  Julia Diegmann; Kerstin Junker; Ivan F Loncarevic; Susanne Michel; Bettina Schimmel; Ferdinand von Eggeling
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

3.  Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.

Authors:  W M Mulder; M J Stukart; M Roos; R A van Lier; J Wagstaff; R J Scheper; E Bloemena
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

Review 4.  Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

5.  Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model.

Authors:  Eric C Kauffman; Huixian Liu; Michael J Schwartz; Douglas S Scherr
Journal:  J Oncol       Date:  2012-02-22       Impact factor: 4.375

6.  Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.

Authors:  U Elsässer-Beile; M Rindsfüser; T Grussenmeyer; W Schultze-Seemann; U Wetterauer
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.